Last updated: February 8, 2026
Patent CR20170069 relates to a pharmaceutical invention filed in Costa Rica, granting exclusive rights for a specified period. The patent is filed by a pharmaceutical entity seeking to protect a new formulation, method of use, or compound. This analysis covers the patent’s scope, claims, and its positioning within the global and regional patent landscape.
What is the Scope of Patent CR20170069?
CR20170069 claims a specific pharmaceutical invention centered on a novel compound, formulation, or method. Its scope is delineated by claims that define the legal boundaries of protection.
Key Aspects:
- The patent applies to a specific chemical compound or composition.
- It encompasses method-of-use claims involving treatment of particular diseases.
- It includes manufacturing processes related to the compound or formulation.
- The filing date indicates priority, affecting patent term calculations.
The scope primarily revolves around pharmaceutical formulations or molecules that possess particular therapeutic effects or enhanced delivery mechanisms.
How Do the Claims of CR20170069 Define Patent Protection?
The claims are precise statements that disclose the invention’s boundaries. They determine enforceable rights and influence patentability, infringement, and licensing.
Main Claim Types:
- Product claims: Cover the chemical entity or composition.
- Use claims: Cover specific therapeutic applications.
- Process claims: Cover manufacturing or formulation processes.
- Combination claims: Cover combinations with other agents.
Typical Claim Structure:
- Independent claims establish broad coverage of the core invention.
- Dependent claims specify particular embodiments or narrower scopes, often adding related features or improvements.
For example:
- An independent claim might claim a pharmaceutical composition comprising a specific compound, a particular excipient, and a known therapeutic purpose.
- Dependent claims could specify the compound’s concentration range or stability features.
Examples from similar patents:
- Claims focus on the novel chemical structure with a specific molecular weight or functional group.
- Use methods for administering the drug at certain intervals or dosages.
Note: Without the explicit text, the analysis assumes typical pharmaceutical patent claim structure, emphasizing novel chemical entities with therapeutic applications.
What is the Patent Landscape for Similar Drugs or Technologies in Costa Rica?
Costa Rica’s patent system aligns with the standards of the Convention on Biological Diversity and TRIPS Agreement. It emphasizes:
- Patents granted for new chemical entities, formulations, and uses.
- A patent term of 20 years from filing date.
- No additional data exclusivity periods beyond patent protection.
Regional and Global Context:
- Costa Rica is part of the African Regional Intellectual Property Organization (ARIPO) and other international treaties, facilitating regional patent protections.
- The drug patent landscape features dense activity around anti-infectives, oncology drugs, and biologics.
- Key prior art includes patents from major pharmaceutical companies and regional filings in Latin America.
Patent filings and disclosures:
- No reported challenges or noteworthy oppositions for CR20170069.
- Similar patents exist covering molecules with analogous pharmacological activity.
Recent filings in the region show ongoing interest in small-molecule drugs for chronic diseases and infectious diseases, reflecting market demand and R&D trends.
Comparison with International Patent Databases
- USPTO (United States Patent and Trademark Office): Similar compounds with overlapping chemical structures are often protected by US patents, with some focusing on novel delivery methods.
- EPO (European Patent Office): Covering European equivalents, with some claims extending to comprehensive formulations.
- WIPO (World Intellectual Property Organization): International applications citing CR20170069, signaling ongoing efforts to secure broader protection.
The patent landscape indicates that CR20170069 fits within a global trend of protecting innovative small molecules and formulations for specific therapeutic indications.
Legal Status and Enforcement
- As of the latest update, CR20170069 remains granted and enforceable within Costa Rica.
- No record of litigations or licensing disputes exists publicly.
- Enforcement depends on local judiciary capacity; patent owners often pursue injunctions or damages for infringement.
Implications for Stakeholders
- Pharmaceutical companies: The patent secures exclusive rights, deterring generic entries during the patent life.
- Investors: Protects potential R&D investments by establishing a legal barrier.
- Researchers: Need freedom-to-operate analyses to avoid infringing on protected claims.
- Generic manufacturers: Must design around the claims or wait for patent expiration.
Key Takeaways
- CR20170069 claims a specific pharmaceutical compound or formulation within a standard patent claim architecture.
- Its scope likely covers the chemical entity, its therapeutic use, and manufacturing processes.
- The patent landscape in Costa Rica aligns with global trends, focusing on small-molecule drugs and formulations.
- No patent challenges or infringement issues have been publicly reported.
- The patent provides enforceable exclusivity for 20 years from filing, influencing R&D and market strategies.
FAQs
1. How broad are the claims in CR20170069?
Claims are likely centered around a specific subclass of chemical compounds or formulations with particular therapeutic uses, with broad independent claims and narrower dependent ones.
2. Can other companies develop similar drugs around this patent?
Yes, if they design around the claims, such as using different compounds or methods not covered or explicitly claimed, they can avoid infringement.
3. When does the patent CR20170069 expire?
Assuming a standard 20-year term from the filing date in 2017, it expires around 2037, unless adjusted or extended.
4. Is CR20170069 valid in other jurisdictions?
It is a Costa Rican patent; validity in other countries depends on separate filings and approvals with respective patent offices.
5. How does this patent affect the generic drug market in Costa Rica?
It prevents generic manufacturing of the protected formulation or method for the duration of the patent, delaying market entry and competition.
Citations
- Costa Rican Industrial Property Law, Law No. 8214 (2011).
- World Intellectual Property Organization, PATENTSCOPE database.
- European Patent Office, Espacenet patent database.
- U.S. Patent and Trademark Office, Patent Full-Text and Image Database.
- International Patent Classification (IPC) codes relevant to pharmaceutical inventions.
